These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 18181204)
1. Dopaminergic drug-induced tics in PARK2-positive Parkinson's disease. Dafotakis M; Fink GR; Nowak DA Mov Disord; 2008 Mar; 23(4):628. PubMed ID: 18181204 [No Abstract] [Full Text] [Related]
2. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
3. An approach to the continuous dopaminergic stimulation in Parkinson's disease. Schwartz M; Sabetay S Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859 [TBL] [Abstract][Full Text] [Related]
4. [Parkinson's disease associated with a mutation in the PARK2 gene]. Kaasinen V; Hietala M; Kuoppamäki M Duodecim; 2015; 131(12):1187-90. PubMed ID: 26245049 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease. Clarke C; Moore A Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943 [No Abstract] [Full Text] [Related]
6. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
7. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW; Obeso JA; Stocchi F Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
10. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
11. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Zappia M; Quattrone A Mov Disord; 2008 May; 23(7):1062-1063. PubMed ID: 17994584 [No Abstract] [Full Text] [Related]
12. New medication recommended for Parkinson's disease. Levenson D Rep Med Guidel Outcomes Res; 2001 Jun; 12(13):7-9. PubMed ID: 12182172 [No Abstract] [Full Text] [Related]
13. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
14. [Etiology and physiopathology of patients with parkinson's disease]. Ogawa N Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1394-9. PubMed ID: 13677885 [No Abstract] [Full Text] [Related]
15. [Progress in diagnosis and therapy for Parkinson's disease]. Mizuno Y Nihon Naika Gakkai Zasshi; 2002 Aug; 91(8):2344-8. PubMed ID: 12373846 [No Abstract] [Full Text] [Related]
17. Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F; Riuggeri RM J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic drugs in development for Parkinson's disease. Korczyn AD Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685 [No Abstract] [Full Text] [Related]
19. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Stathis P; Konitsiotis S; Antonini A Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445 [TBL] [Abstract][Full Text] [Related]